Journal Basic Info
- Head and Neck Oncology
- Radiation Oncology
- Lung Cancers
- Adjuvant Therapy
- Gastrointestinal Cancer
- Breast Cancer
- Neoadjuvant Therapy
- Surgical Oncology
Citation: Clin Oncol. 2022;7(1):1916.DOI: 10.25107/2474-1663.1916
Akira Okimura, Hiroshi Hirano, Yumika Ito, Midori Wakiy and Munehide Nakatsugawa
Department of Diagnostic Pathology, Hachioji Medical Center, Tokyo Medical University, Japan
The major pathogenetic factor for a malignant mesothelioma is asbestos exposure. Cases have recently been increasing, thus clinicians are faced with more instances where a correct diagnosis is required and require information regarding features of this tumor. A malignant mesothelioma can be classified into three subtypes; epithelioid, sarcomatoid, and biphasic, with differential
diagnosis varying for each subclass. There are two categories for the differentiation of an epithelioid mesothelioma depending on whether the cells are benign or malignant. The former is mesothelial cell proliferation and the latter malignant epithelial neoplasm, which includes a metastatic carcinoma arising from a site other than the pleura.
Various types of sarcomas are listed under sarcomatoid mesothelioma, while associated with biphasic carcinoma are carcinosarcoma and synovial sarcoma, biphasic type. Furthermore, it is important to understand rare features of a malignant mesothelioma. This review presents the pathological features of malignant mesothelioma including rare histological subtypes.
Malignant mesothelioma; Immunohistochemistry; Differential diagnosis
Cite the Article:
Okimura A, Hirano H, Ito Y, Wakiy M, Nakatsugawa M. Malignant Mesothelioma. Clin Oncol. 2022;7:1916..